Featured Research

from universities, journals, and other organizations

Insulin's risks as second-line medicine to treat type 2 diabetes

Date:
June 11, 2014
Source:
Vanderbilt University Medical Center
Summary:
Adults with type 2 diabetes who take insulin in addition to the recommended first-line drug therapy, metformin, had a 30 percent higher risk of heart attack, stroke or death when compared to similar patients who instead augment their metformin regimen with a sulfonylurea, research shows. New heart attacks and strokes occurred at similar rates in both groups but death (from all causes) was 44 percent higher in patients who added insulin compared to those who added a sulfonylurea.

In an observational study by researchers at Vanderbilt University Medical Center, adults with type 2 diabetes who take insulin in addition to the recommended first-line drug therapy, metformin, had a 30 percent higher risk of heart attack, stroke or death when compared to similar patients who instead augment their metformin regimen with a sulfonylurea.

New heart attacks and strokes occurred at similar rates in both groups but death (from all causes) was 44 percent higher in patients who added insulin compared to those who added a sulfonylurea.

The study appeared this week in the Journal of the American Medical Association (JAMA), highlighted with an accompanying editorial and an online video interview with lead author Christianne Roumie, M.D., MPH, associate professor of Medicine and Pediatrics.

Roumie and colleagues compared medical records of two groups of Veterans Health Administration patients with diabetes: 2,436 who took metformin and insulin, and 12,180 who instead took metformin and one or another type of sulfonylurea. The research team accounted for patient co-morbidities, age, duration of treatment, smoking status, sex, race and physiologic variables, including diabetes control.

Some 26 million Americans have diabetes (type 2 accounts for between 90 and 95 percent of all diabetes in the United States). Diet and exercise often provide an effective first-line intervention for this disease, but many patients require a medication, and metformin is recommended as a first-line treatment. Many patients eventually require additional medicines, and according to Roumie the choice of a second medication has been less clear.

"A couple of small clinical trials have shown that using insulin earlier in a disease course helps preserve beta cells in your pancreas longer," she said. On the other hand, "multiple large clinical trials have found either no benefit or potential harm from attempting very tight management of glucose. We wanted to look within a real-world practice at the drugs that patients use and evaluate the outcomes."

In a statement accompanying the study, Roumie wrote, "Although adding insulin seems a reasonable option for some patients who have very high glucose or who desire flexible and fast blood sugar control, the study findings suggest that for most patients who need a second diabetes drug, adding a sulfonylurea to metformin should be preferred to adding insulin."

At present, any underlying mechanism that might explain the increased risk of death found in the study remains unknown. Roumie and colleagues have a number of studies planned to examine possible mechanisms, and are now investigating type 2 diabetes outcomes associated with blood glucose swings and with episodes of hypoglycemia (low blood sugar) tied with insulin use.

Roumie was joined in the study by Vanderbilt investigators Robert Greevy, Ph.D.; Carlos Grijalva, M.D., MPH; Adriana Hung, M.D., MPH; Xulei Liu, M.D., MS; Harvey Murff, M.D., MPH; Tom Elasy, M.D., MPH; and Marie Griffin, M.D., MPH.

The study was performed under the aegis of Vanderbilt's DEcIDE Center (Developing Evidence to Inform Decisions about Effectiveness), and was supported by the Agency for Healthcare Research and Quality, the National Institutes of Health (grant DK092986) and the Department of Veterans Affairs.


Story Source:

The above story is based on materials provided by Vanderbilt University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christianne L. Roumie, Robert A. Greevy, Carlos G. Grijalva, Adriana M. Hung, Xulei Liu, Harvey J. Murff, Tom A. Elasy, Marie R. Griffin. Association Between Intensification of Metformin Treatment With Insulin vs Sulfonylureas and Cardiovascular Events and All-Cause Mortality Among Patients With Diabetes. JAMA, 2014; 311 (22): 2288 DOI: 10.1001/jama.2014.4312

Cite This Page:

Vanderbilt University Medical Center. "Insulin's risks as second-line medicine to treat type 2 diabetes." ScienceDaily. ScienceDaily, 11 June 2014. <www.sciencedaily.com/releases/2014/06/140611102105.htm>.
Vanderbilt University Medical Center. (2014, June 11). Insulin's risks as second-line medicine to treat type 2 diabetes. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2014/06/140611102105.htm
Vanderbilt University Medical Center. "Insulin's risks as second-line medicine to treat type 2 diabetes." ScienceDaily. www.sciencedaily.com/releases/2014/06/140611102105.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Costs Keep Mounting

Ebola Costs Keep Mounting

Reuters - Business Video Online (Sep. 23, 2014) The WHO has warned up to 20,000 people could be infected with Ebola over the next few weeks. As Sonia Legg reports, the implications for the West African countries suffering from the disease are huge. Video provided by Reuters
Powered by NewsLook.com
Ebola Cases Could Reach 1.4 Million Within 4 Months

Ebola Cases Could Reach 1.4 Million Within 4 Months

Newsy (Sep. 23, 2014) Health officials warn that without further intervention, the number of Ebola cases in Liberia and Sierra Leone could reach 1.4 million by January. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Cases to Triple in Weeks Without Drastic Action

WHO: Ebola Cases to Triple in Weeks Without Drastic Action

AFP (Sep. 23, 2014) The number of Ebola infections will triple to 20,000 by November, soaring by thousands every week if efforts to stop the outbreak are not stepped up radically, the WHO warned in a study on Tuesday. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
5 Ways Men Can Prevent Most Heart Attacks

5 Ways Men Can Prevent Most Heart Attacks

Newsy (Sep. 23, 2014) No surprise here: A recent study says men can reduce their risk of heart attack by maintaining a healthy lifestyle, which includes daily exercise. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins